Indo US Bio-Tech

Why is Indo US Bio-Tech Ltd falling/rising?

As of 26-Jul, Indo US Bio-Tech Ltd's stock price is at Rs. 85.01, down 1.3% and reaching a new 52-week low. The stock is underperforming significantly, with a year-to-date decline of 30.43%, despite increased investor participation.

As of 26-Jul, Indo US Bio-Tech Ltd's stock price is falling, currently at Rs. 85.01, reflecting a decrease of Rs. 1.12 or 1.3%. The stock has been underperforming, with a performance today that is 3.78% lower than its sector. Additionally, it has experienced consecutive declines over the last two days, resulting in a total drop of 2.72% during this period. <BR><BR>The stock has also reached a new 52-week low of Rs. 84.96 today. It is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Year-to-date, the stock has decreased by 30.43%, significantly underperforming compared to the Sensex, which has only fallen by 10.75% during the same period. <BR><BR>Despite a rise in investor participation, with delivery volume increasing by 78.56% against the 5-day average, the overall sentiment remains negative, contributing to the stock's decline.

Which are the latest news on Indo US Bio-Tech?

What does Indo US Bio-Tech do?

Indo US Bio-Tech Ltd is a Micro Cap company in the Other Agricultural Products industry, reporting net sales of 26 Cr and a net profit of 2 Cr for March 2026. It was incorporated in 2004 and became a public company in 2018, with a market cap of INR 191 Cr.

Overview: <BR>Indo US Bio-Tech Ltd operates in the Other Agricultural Products industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated as "Pollucid Bio-Tech Private Limited" in 2004. It underwent several name changes, becoming "Indo Us Bio-Tech Private Limited" in 2007 and later "Indo Us Bio-Tech Limited" upon conversion to a Public Limited Company in 2018. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 26 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 191 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 36 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.31 <BR>Return on Equity: 15.14% <BR>Price to Book: 2.20 <BR><BR>Contact Details: <BR>Address: 309 Shanti Mall, Satadhar Char Rasta Sola Road Ahmedabad Gujarat : 380061 <BR>Tel: 91-79-27491807 <BR>Email: compliance@indousagriseeds.com <BR>Website: http://www.indousagriseeds.com

How big is Indo US Bio-Tech?

As of 10th June, Indo US Bio-Tech Ltd has a market capitalization of 191.00 Cr, with recent net sales of 110.44 Cr and a net profit of 13.12 Cr. Shareholder's funds are 38.51 Cr, and total assets amount to 55.20 Cr as of March 2022.

As of 10th June, Indo US Bio-Tech Ltd has a market capitalization of 191.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 110.44 Cr and a Net Profit of 13.12 Cr.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds amounting to 38.51 Cr and Total Assets of 55.20 Cr.

Who are in the management team of Indo US Bio-Tech?

The management team of Indo US Bio-Tech includes Jagdish Ajudia (Chairman & Managing Director), Maltiben Ajudia (Whole-time Director), Priyanka Ajudia (Executive Director), Ritaben Nileshbhai Kikani (Non-Executive & Independent Director), and Dimpy Joshi (Company Secretary).

The management team of Indo US Bio-Tech includes the following individuals:<BR><BR>1. **Jagdish Ajudia** - Chairman & Managing Director<BR>2. **Maltiben Ajudia** - Whole-time Director<BR>3. **Priyanka Ajudia** - Executive Director<BR>4. **Ritaben Nileshbhai Kikani** - Non-Executive & Independent Director<BR>5. **Dimpy Joshi** - Company Secretary<BR><BR>If you need more information about their roles or the company's activities, feel free to ask!

Who are the peers of the Indo US Bio-Tech?

Indo US Bio-Tech's peers include Halder Venture, Tierra Agrotech, Nag. Agri Tech, JK Agri Genetics, MANGALAM SEEDS, Harshdeep Horti, Shivashrit Foods, and Sawaliya Food. While Indo US Bio-Tech has good management risk and average growth, it has the lowest 1-year return at -46.60% compared to its peers.

Peers: The peers of Indo US Bio-Tech are Halder Venture, Tierra Agrotech, Nag. Agri Tech., JK Agri Genetics, MANGALAM SEEDS, Harshdeep Horti., Shivashrit Foods, and Sawaliya Food.<BR><BR>Quality Snapshot: Excellent management risk is observed at Harshdeep Horti., Shivashrit Foods, and Sawaliya Food, while Good management risk is found at Indo US Bio-Tech, Nag. Agri Tech., and the rest. Average management risk is noted at Halder Venture and JK Agri Genetics, while Below Average management risk is seen at Tierra Agrotech and the rest. Growth is Excellent at Sawaliya Food, Good at Nag. Agri Tech., MANGALAM SEEDS, Harshdeep Horti., and the rest, Average at Indo US Bio-Tech, and Below Average at Halder Venture, JK Agri Genetics, and Tierra Agrotech. Capital Structure is Excellent at Harshdeep Horti., Good at Indo US Bio-Tech, Nag. Agri Tech., and Sawaliya Food, Average at MANGALAM SEEDS, and Below Average at Halder Venture, JK Agri Genetics, and Tierra Agrotech.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Halder Venture at 227.86%, while Indo US Bio-Tech has the lowest at -46.60%. This shows that Indo US Bio-Tech's return is significantly lower than its peers. Additionally, the six-month return is negative for Halder Venture, Tierra Agrotech, JK Agri Genetics, MANGALAM SEEDS, and Nag. Agri Tech.

Should I buy, sell or hold Indo US Bio-Tech Ltd?

When is the next results date for Indo US Bio-Tech Ltd?

The next results date for Indo US Bio-Tech Ltd is January 21, 2026.

The next results date for Indo US Bio-Tech Ltd is scheduled for January 21, 2026.

Is Indo US Bio-Tech overvalued or undervalued?

As of December 4, 2025, Indo US Bio-Tech is considered very attractive and undervalued, with a PE ratio of 15.32, strong growth potential indicated by a PEG ratio of 0.35, and solid financial performance metrics, despite a year-to-date stock performance lagging behind the Sensex.

As of 4 December 2025, the valuation grade for Indo US Bio-Tech has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 15.32, an EV to EBITDA of 14.47, and a PEG ratio of 0.35, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Indo US Bio-Tech stands out with a significantly lower PE ratio than Jain Irrigation at 52.39 and Krishival Foods at 77.88, both of which are considered very expensive. Additionally, the company’s ROE of 19.48% and ROCE of 16.37% further reinforce its strong financial performance. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -59.05% compared to the Sensex's 9.12%, the underlying fundamentals suggest that Indo US Bio-Tech is positioned for recovery and growth.

How has been the historical performance of Indo US Bio-Tech?

Indo US Bio-Tech has shown steady growth over the past three years, with net sales increasing from 39.76 crore in March 2020 to 50.06 crore in March 2022, and profit after tax rising from 2.53 crore to 5.06 crore. Despite rising raw material costs, the company improved its operational efficiency and cash flow during this period.

Answer:<BR>The historical performance of Indo US Bio-Tech shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Indo US Bio-Tech's net sales increased from 39.76 crore in March 2020 to 50.06 crore in March 2022, reflecting a positive trend in revenue generation. The total operating income followed the same trajectory, rising from 39.76 crore in March 2020 to 50.06 crore in March 2022. However, raw material costs surged significantly from 3.59 crore in March 2020 to 45.20 crore in March 2022, indicating increased operational expenses. Despite this, the operating profit (PBDIT) improved from 3.99 crore in March 2020 to 6.95 crore in March 2022, showcasing better operational efficiency. Profit before tax also rose from 2.86 crore in March 2020 to 5.31 crore in March 2022, while profit after tax increased from 2.53 crore to 5.06 crore in the same period. The company's total assets grew from 34.70 crore in March 2020 to 55.20 crore in March 2022, alongside a rise in total liabilities from 34.70 crore to 55.20 crore. Cash flow from operating activities showed a positive trend, moving from 0.00 crore in March 2021 to 2.00 crore in March 2022, indicating improved cash generation capabilities. Overall, Indo US Bio-Tech has demonstrated consistent growth in sales, profits, and asset accumulation over the past three years.

Are Indo US Bio-Tech latest results good or bad?

Indo US Bio-Tech's latest results show strong year-on-year growth, with a 127.10% increase in Profit After Tax and a 58.43% rise in net sales. However, recent quarterly performance indicates a 7.82% decline in net sales, leading to a cautious outlook, as reflected by MarketsMOJO's 'Sell' recommendation.

Indo US Bio-Tech's latest financial results present a mixed picture. On one hand, the company has demonstrated significant growth in profitability, with a Profit After Tax (PAT) of Rs 8.38 crore for the last six months, reflecting a remarkable year-on-year increase of 127.10%. Additionally, net sales reached Rs 64.15 crore, marking a solid growth of 58.43% compared to the previous year.<BR><BR>However, there are some concerns to note. The quarterly performance for the period ending June 2025 shows a decline in net sales by 7.82% compared to the previous quarter, which contrasts sharply with the strong growth of 41.68% seen in March 2025. While the standalone net profit did increase by 27.72% quarter-on-quarter, the overall trend indicates some volatility.<BR><BR>Despite these positive growth figures, MarketsMOJO has issued a 'Sell' call on the stock, suggesting that there may be underlying concerns that investors should consider. Overall, while there are positive indicators in terms of year-on-year growth, the recent quarterly performance raises some caution about the company's short-term trajectory.

Who are the top shareholders of the Indo US Bio-Tech?

The top shareholder of Indo US Bio-Tech is Jagdishkumar Devjibhai Ajudiya, holding 48.82%. Other notable shareholders include Improwised Technologies Private at 1.99% and individual investors with a collective 24.34%.

The top shareholders of Indo US Bio-Tech include the promoters, with Jagdishkumar Devjibhai Ajudiya holding the largest share at 48.82%. There are no pledged promoter holdings, and the company does not have any mutual fund schemes invested in it. Additionally, there is one Foreign Institutional Investor (FII) with a very minimal holding of 0.0%. The highest public shareholder is Improwised Technologies Private, which holds 1.99%. Individual investors collectively hold 24.34% of the shares.

What is the technical trend for Indo US Bio-Tech?

As of May 26, 2025, the market trend is mildly bearish, with daily moving averages and weekly Bollinger Bands indicating bearish signals, despite some mixed indicators like the MACD and KST showing mild bullishness in the short term.

As of 26 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a bearish signal. The MACD presents a mixed picture with a mildly bullish signal on the weekly but mildly bearish on the monthly. The KST aligns with this by being mildly bullish weekly and mildly bearish monthly. The OBV is consistently mildly bearish across both time frames. Overall, while there are some mildly bullish indicators, the prevailing sentiment remains bearish, particularly in the short term.

What is the bonus history of the Indo US Bio-Tech?

Indo US Bio-Tech has a history of issuing bonus shares, with the most recent being a 1:1 bonus on August 29, 2023, following a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This reflects the company's commitment to rewarding its shareholders.

Indo US Bio-Tech has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of August 29, 2023. Prior to that, the company issued a 1:5 bonus on November 29, 2021, and a 1:4 bonus on April 23, 2019. This shows a consistent approach to rewarding shareholders through bonus shares over the years.

Has Indo US Bio-Tech declared dividend?

Indo US Bio-Tech Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of December 3, 2024. Recent total returns have shown significant volatility, with a total return of -42.67% over the last 6 months, but positive long-term returns over 2, 3, 4, and 5 years.

Indo US Bio-Tech Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 03 Dec 2024<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -42.67%, with a dividend return of 0%, resulting in a total return of -42.67%.<BR><BR>Over the past year, the price return was -22.47%, the dividend return was 0.09%, leading to a total return of -22.38%.<BR><BR>In the 2-year period, the price return was 42.53%, with a dividend return of 0.19%, resulting in a total return of 42.72%.<BR><BR>For the 3-year period, the price return was 472.63%, the dividend return was 0.71%, culminating in a total return of 473.34%.<BR><BR>In the last 4 years, the price return was 962.85%, with a dividend return of 2.39%, leading to a total return of 965.24%.<BR><BR>Over the past 5 years, the price return was 686.51%, with a dividend return of 2.09%, resulting in a total return of 688.6%.<BR><BR>Overall, while Indo US Bio-Tech has declared a dividend, the recent total returns show significant volatility, particularly in the shorter periods, indicating a challenging performance in the near term despite positive long-term returns.